SEK 13.15
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Annexin Pharmaceuticals AB (publ) is a biotechnology firm dedicated to developing innovative therapeutic agents aimed at addressing a wide range of cardiovascular conditions. A cornerstone of their pipeline is ANXV, a specifically engineered human recombinant protein. This protein, which utilizes Annexin A5, is designed to both protect and repair blood vessels while actively mitigating inflammatory responses. The company was established in 2014 and maintains its headquarters in Stockholm, Sweden.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only